Rationale Behind the Recent FDA PD-1 Inhibitor Label Restrictions

Posted on by admin

Ron Lanton, Partner, Lanton Law, discusses why the regulatory body made the decision to place restrictions on PD-1 inhibitors for gastric cancers.

Leave a Reply

Your email address will not be published. Required fields are marked *